Back to search

National and Kapodistrian University of Athens

Προγνωστικοί παράγοντες διατήρησης της ύφεσης μετά τη διακοπή αντιικών σε ασθενείς με HBeAg-αρνητική χρόνια ηπατίτιδα Β

Abstract

dc:description

Background: Patient outcomes after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B (CHB) vary widely among studies, while reliable predictors of relapse and/or retreatment as well as HBsAg loss have not been identified. This prospective study assessed rates and predictors of the abovementioned outcomes and investigated the kinetics of hepatitis B surface antigen (HBsAg), interferon inducible protein-10 (IP10) and hepatitis B core related antigen (HBcrAg) serum levels in non-cirrhotic HBsAg positive patients with HBeAg-negative CHB who discontinued effective ≥4- year entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy. Methods: Fifty-seven patients discontinued therapy after median virological remission of 5.3 years and remained under close follow-up. Patients were retreated with ETV or TDF if they fulfilled predetermined criteria and were followed monthly for 3 months, every 2 or 3 months until month 12 and every 3 or 6 months thereafter. HBsAg, IP10 and HBcrAg serum levels were measured by enzyme immunoassays and SCALE-B score was calculated.Results: During median follow-up of 18 months, no patient died, developed jaundice or liver decompensation. The cumulative relapse rates varied widely according to HBV DNA and ALT cut-offs; for HBV DNA >2000 IU/mL, they were 56%, 70% and 72% at 3, 12 and 18 months after stopping ETV/TDF. The cumulative probability of retreatment was 18% and 26% at 3 and 12 months and independent predictors of retreatment were pretreatment fibrosis severity and HBcrAg serum levels at ETV/TDF discontinuation. Twelve patients achieved HBsAg loss before retreatment with 18-month cumulative incidence of 25%. Independent predictors of HBsAg loss were baseline HBsAg and month-1 IP10 levels. Of 10 patients with baseline HBsAg ≤100 IU/mL, 70% cleared HBsAg and 10% required retreatment. Of 23 patients with baseline HBsAg >1000 IU/mL, 4% cleared HBsAg and 43% required retreatment. Of 24 patients with intermediate baseline HBsAg (100-1000 IU/mL), 17% cleared HBsAg and 21% required retreatment; in this subgroup, month-1 IP10 was significantly associated with HBsAg loss, which occurred in 30% and 7% of cases with IP10 >150 and ≤150 pg/mL, respectively. Baseline HBcrAg was undetectable in all patients who cleared HBsAg. SCALE-B was associated with HBsAg loss but not with relapse or retreatment.Conclusions: Our prospective study shows that effective ≥4-year ETV/TDF therapy can be safely discontinued in non-cirrhotic HBeAg-negative CHB patients. Despite common virological relapses, most patients, particularly those with mild-moderate pretreatment fibrosis and/or undetectable HBcrAg, remain without retreatment, at least during the first 18 months, while one in four patients clear HBsAg and the majority of the others eventually remains in post-NA remission. Furthermore, HBsAg, IP10 and HBcrAg serum levels have been shown to be predictive markers for guiding the decisions of stopping and restarting therapy in non-cirrhotic Caucasian patients with HBeAg-negative CHB.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papatheodoridi, Margarita
  • Παπαθεοδωρίδη, Μαργαρίτα

Subjects

dc:subject × 13

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/46509

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papatheodoridi, Margarita; Παπαθεοδωρίδη, Μαργαρίτα. Προγνωστικοί παράγοντες διατήρησης της ύφεσης μετά τη διακοπή αντιικών σε ασθενείς με HBeAg-αρνητική χρόνια ηπατίτιδα Β. National and Kapodistrian University of Athens, 2019. http://hdl.handle.net/10442/hedi/46509